About this compound
Combination of long-acting amylin analog (Cagrilintide) and GLP-1 analog (Semaglutide). Studied for synergistic activity on glucose and appetite signaling pathways.
Specification
| Compound | CagriSema |
| Class | Co-administered amylin + GLP-1 combination |
| Form | Lyophilized powder |
| Purity | >99% HPLC — verified by two independent labs |
| Storage | Lyophilized: 2–8°C protected from light. Reconstituted: −20°C, use within 28 days. Avoid freeze–thaw cycles. |
Reported research areas
- Combined incretin/amylin research
- Metabolic signaling integration studies
Selected references
- Enebo et al. 2021 — PMID 34044112
Independent verification
Every batch is tested by Janoshik Analytical (Czech Republic, HPLC + MS) and Aethos Bioanalytics (US, independent HPLC + LAL endotoxin where applicable). Both Certificates of Analysis are published on this product page — never edited, never curated. If the two labs disagree on purity by more than 0.5%, the entire lot is destroyed.
Disclaimer
FOR RESEARCH USE ONLY. Not for human consumption. No diagnostic or therapeutic use. By purchasing this product, you affirm you are using it strictly for laboratory research purposes in a controlled setting.
Reviews
There are no reviews yet.